VP# [004]

Related by string. VP# [002] . VP# [001] . VP# [003] * * Xsigo VP# . MetaSwitch VP# . DVDO iScan VP# . iScan VP# . VP# protein . KD VP# *

Related by context. Frequent words. (Click for all words.) 67 tumor lysis syndrome 66 tigecycline 66 receiving VELCADE 66 forodesine 65 administered subcutaneously 65 ganciclovir 65 hemoptysis 65 hypophosphatemia 65 nosocomial pneumonia 65 hypomagnesemia 65 nephrotoxicity 64 QTc prolongation 64 Streptococcus pyogenes 64 refractory chronic lymphocytic 64 daptomycin 64 trimethoprim sulfamethoxazole 64 DDP# 64 HCV genotypes 64 teriflunomide 64 neutropenia thrombocytopenia 64 bacteraemia 64 voriconazole 64 Pivotal Phase III 64 pheochromocytoma 64 superficial bladder cancer 64 hypercalcemia 63 nonclinical studies 63 Initiate Phase 63 peginterferon alfa 63 Fibrillex TM 63 corticosteroid therapy 63 Traficet EN 63 cidofovir 63 hematologic toxicity 63 TELINTRA 63 TYGACIL 63 APTIVUS r 63 APTIVUS 62 Dasatinib 62 PROMACTA 62 heparin induced thrombocytopenia 62 peripheral blood mononuclear 62 amikacin 62 hepatic failure 62 rFVIIa 62 dose limiting toxicities 62 R sorafenib tablets 62 Golimumab 62 PEG SN# 62 TTR amyloidosis 62 ISTODAX 62 pericardial effusion 62 pharmacokinetic PK 62 interferon alfa 2b 62 CYC# 62 Solid Tumors 62 Diabetic Neuropathy 62 bacteremia 62 PREZISTA r 62 Antifungal 62 Recombinant Human 62 Eculizumab 62 CCX# 62 intravenous immunoglobulin 62 ethambutol 62 methicillin resistant S. aureus 62 CMV infection 62 AVELOX 62 intravesical 62 Cethromycin 62 CR# vcMMAE 62 squalamine 62 Lubiprostone 62 Eltrombopag 62 immunohistochemical 62 Epidermal Growth Factor Receptor 61 HGS ETR2 61 pharmacodynamic effects 61 bleomycin 61 PRADAXA 61 CIMZIA TM 61 GnRH agonists 61 Meets Primary Endpoint 61 Pivotal Phase 61 fluvastatin 61 Capecitabine 61 calcineurin inhibitors 61 renal toxicity 61 NPH insulin 61 Clinical Trial Results 61 Immunogenicity 61 highly immunogenic 61 inflammatory autoimmune diseases 61 indinavir 61 AEG# 61 unknown etiology 61 Tacrolimus 61 Preclinical Data 61 Epratuzumab 61 hepatocellular 61 Initiates Phase II

Back to home page